Summary
This systematic review and meta-analysis asked whether herbal medicine treats chronic fatigue syndrome (CFS) after COVID-19. It included 15 randomized controlled trials (RCTs), all conducted in Asia, and screened databases for studies published January 1, 2020 to August 31, 2024. Treatments were herbal formulas or single medicinal herbs, given for varied durations, and were compared with placebo granules, Western medicine, or conventional herbal medicines. Outcomes included total effective rate, Chalder’s Fatigue Scale (ChFS), Fatigue Scale-14 (FS-14), FSS, CIS, SF-36, and other symptom or quality-of-life scales. Findings were mixed. A meta-analysis reported statistically significant improvements for herbal treatments compared with Western medicine and conventional herbal medicine in most studies. Individual trials also reported some improvements, but several showed no significant intergroup difference: Shin (CIS P=0.210), Li (total effective rate P>0.05), Choi (FSS, MFI-20, ChFS, biomarkers), Dai, Kan, and Sung (all items). Reported side effects were mild or unrelated symptoms and included flushing, headache, heartburn, migraine, dermatitis, nausea, lower abdominal pain, dizziness, diarrhea, cold, fracture, toothache, and upper respiratory infection. Dropout rates were 17.3% in Dai and 7.9% in Kan. The authors state the search period was short and included studies had small patient numbers; they also note most studies came from China, overall quality was low, and heterogeneity was high.